Next Phase Newsletter

A healthcare investment firm based in the USA with multiple billion dollars in assets under management. The firm invests in life science companies and is currently investing out of its fifth fund. The firm looks to invest in companies globally, with a focus on companies located in the United States.

The firm is interested in therapeutics, medical devices and diagnostics, although the majority of the firm’s investments have been in the therapeutics space. The firm is primarily interested in Series A, B, and C opportunities, with a focus on therapeutics that have strong preclinical data or are peri-clinical. The firm also has special interests in oncology, infectious diseases, rare diseases, dermatology and autoimmune disorders.

The firm is looking for companies with significant competitive advantage and strong, experienced management teams. The firm is willing to invest in both publicly and privately held companies. The firm is open to both lead and co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The firm is a venture fund based in San Diego, California, founded in 2021. The firm has $750 AUM for their first fund and will invest from early to later stage companies. The firm is interested in therapeutics, companion diagnostics, precision medicine, tools and manufacturing services. The firm generally invests $10M or more, but may participate in earlier rounds, primarily as a fund of funds. The firm will invest globally, and prefers companies developing platform technologies or with multiple assets.

Within therapeutics, the firm is interested in small molecules, biologics and cell and gene therapies. Outside of therapeutics, the firm is interested in companion diagnostics, precision medicine, life science tools, and novel manufacturing technologies. Indications of interest include oncology/IO, neurodegeneration, autoimmune disorders, cardiometabolic disorders and rare diseases. The firm is willing to invest from pre-IND all the way to PIPEs.

The firm is willing to lead or co-invest, but is a very active investor, and will take at least one board seat after investment. As an individual investor, the firm prefers to invest at least $10M per company, but may invest in smaller rounds as an LP of another investment firm.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

By Karen Deyo, Director of Investor Research, Israel BD, LSN

As many around the world prepare for a litany of winter holidays celebrated globally, the early-stage life science and healthcare world enthusiastically awaits the start of their own winter festival: JPM Week. Whether virtual, in-person, or hybrid, events associated with JPM Week are expected to fill up with buyers and sellers seeking connections and to make deals.

At Digital RESI JPM, attendees can expect an agenda packed with investor panel discussions, insightful tales from the road from successful entrepreneurs, pitch sessions, educational workshops, and more – all designed to help the early-stage entrepreneur understand their audience and make the connections that best match their product and stage of development. Check out the Digital RESI JPM agenda below and sign up by December 17 to save $200!

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Last month, Life Science Nation wrapped up its final Innovator’s Pitch Challenge (IPC) of the year. While the team is busy preparing for our next one at JPM Week, January 11-13, we would be remiss not to announce and celebrate the winners of the Digital RESI November IPC!

1st Place Sana Health	2nd Place Braingrade	3rd Place MOWOOT

Learn more about our winners and how they are shaping the early-stage ecosystem with their technology. Winners are chosen by the votes of our attendees who can access their dedicated landing pages and pitch materials, as well as participate in the live Q&A session. If you’re interested in joining the next IPC, applications are open until December 17. Applications are accepted on a rolling basis, so send yours in today!

FDA Breakthrough device designation for fibromyalgia (class II), Sana is an audiovisual neuormodulation device that gives anxiety relief on demand, giving it applications across pain, mental health and long covid. We have recently completed a pivotal study in Fibromyalgia with Duke, which will be submitted to the FDA as a Denovo in the next month. We also have a pivotal study underway in Neuropathic pain at Mount Sinai, and two more pivotals in Anxiety and PTSD due to start in Q1. We recently were awarded a DoD grant for PTSD. We are on market under a 513g Designation as a wellness device, allowing for speedy clinical trials and adoption. Future areas – depression, lower back pain and long covid. The user puts on the device, and pulses of light and sound induce deep relaxation or sleep within 16 minutes.

Braingrade is developing a brain co-processor, the next-generation brain-machine interface to enhance human cognition. As it?s first indication, the company is targeting Alzheimer?s Disease (AD). The Braingrade memory implant is a fully implantable (invisible, under the skin) deep brain stimulator. The device is capable of detecting abnormal neural activity across multiple brain regions and applying AI-optimized, patterned, electrical stimulation to rectify affected memory circuit oscillations and restore healthy brain activity. It does this through novel probes that use a new material allowing more electrodes at a smaller scale. Braingrade is comprised of a team of experts in all facets of neuro-engineering, with a proven track record of collectively developing and commercialising neuromodulation devices and includes executives and founders of Neuralink, Paradromics & Blackrock as well as DARPA Scientists.

MOWOOT is a growth stage medical device company treating intestinal transit disorders with a novel, purely physical, non-drug, non-invasive solution.

By Rory McCann, Marketing Manager & Conference Producer, LSN

Panel discussions are a popular feature at RESI partnering events. They are valuable tools for entrepreneurs to gather insight from those who are further up the road they are walking and can illuminate what hurdles they may encounter on their own fundraising journey. As the team at Life Science Nation prepares panels for Digital RESI JPM, we want to take the opportunity to share a sample of panel discussions at the past event.

Do you or a colleague have their own experience to share at Digital RESI JPM? Let us know and check out our lineup for next month’s virtual event. Looking to connect with investors and learn from colleagues in your industry? Sign up today to save $200 on early-bird rates!

Clinical & Research Data

Tales from the Road (RESI)

Women in Age-Tech

Impact Investors

By Rory McCann, Marketing Manager & Conference Producer, LSN

As Digital RESI November closes today, the team at Life Science Nation is looking ahead to Digital RESI JPM, January 11-13, 2022. In addition to RESI’s powerful partnering system, the virtual panels are a highlight for investors and fundraising entrepreneurs alike. RESI panels feature industry innovators and subject matter experts to discuss navigating the early-stage ecosystem within life science and healthcare, tackling topics relevant to fundraising and company-building.

Is there a topic you’d like to see at Digital RESI JPM? Would you recommend a particular industry expert or prolific investor to speak to fundraising in this space? We want to hear from you and highlight the issues and stories that are most meaningful to the RESI community. Send your suggestions to RESI@lifesciencenation.com and sign up for Digital RESI JPM by Friday, November 28 to save $300!